Report Phase 1b patient data for YTX-7739 in Parkinson’s disease
Delivered after the deadline (133 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- 10 Nov 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“2Q 2021 – Ph 1b Patient Data”
What we found
Evidence strength A What the grades mean
The company announced the Phase 1b patient data on November 10, 2021, which occurred after the second quarter 2021 deadline.
-
A Yumanity Therapeutics, Inc. 10-K filed 2022-03-24
“On November 10, 2021, we announced top-line data from our Phase 1b clinical trial of YTX-7739 in patients with mild-to-moderate Parkinson’s disease.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 1b patient data for YTX-7739
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Yumanity Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C445283-021530 · Corrections policy